Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loette Diario versus SPIOMET in adolescent girls with hyperinsulinemic ovarian androgen excess
ISRCTN11062950Phase 3Completed
- Sponsor
- Sant Joan de Déu Hospital
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levonorgestrel + ethinyl estradiol, spironolactone, pioglitazone and metformin in polycystic ovary syndrome (PCOS) and Ovarian hyperandrogenism (2 arms), sponsored by Sant Joan de Déu Hospital. Primary endpoints: Insulinemia, Visceral and hepatic fat and 1 more. Started Dec 2015; status: completed.
02
Drugs
levonorgestrel + ethinyl estradiolspironolactonepioglitazonemetformin
03
Conditions
polycystic ovary syndrome (PCOS)Ovarian hyperandrogenism
Beyond the preview
Go deeper on ISRCTN11062950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11062950.